The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market

[1]  J. Kellum,et al.  Acute kidney injury. , 2021, BMJ clinical evidence.

[2]  Ming‐Lung Yu,et al.  Hepatitis C treatment from “response‐guided” to “resource‐guided” therapy in the transition era from interferon‐containing to interferon‐free regimens , 2017, Journal of gastroenterology and hepatology.

[3]  B. Bettencourt,et al.  Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  Mitchell A Jackson,et al.  Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment , 2017, Current opinion in ophthalmology.

[5]  V. Planté-Bordeneuve,et al.  Neurologic Manifestations of Systemic Disease ( N Scolding and C Rice , Section Editors ) Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy , 2016 .

[6]  Seth M. Dever,et al.  Mammalian microRNA: an important modulator of host-pathogen interactions in human viral infections , 2016, Journal of Biomedical Science.

[7]  R. Darcy,et al.  Oligonucleotide conjugates - Candidates for gene silencing therapeutics. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[8]  F. Muñoz-Negrete,et al.  Results of Phase IIB SYLTAG clinical trial with bamosiran in patients with glaucoma , 2016 .

[9]  F. Muñoz-Negrete,et al.  Results of clinical trials with a novel RNA-based therapy (SYL1001) to treat patients with ocular pain associated to dry eye disease , 2016 .

[10]  O. Pelkonen,et al.  Cardiac safety of ophthalmic timolol , 2016, Expert opinion on drug safety.

[11]  N. Chaves,et al.  Suppression of the Eag1 potassium channel sensitizes glioblastoma cells to injury caused by temozolomide , 2016, Oncology letters.

[12]  Allison M. Zimmerman,et al.  Dry Eye Disease: Present Challenges in the Management and Future Trends. , 2016, Current pharmaceutical design.

[13]  N. Ahmad,et al.  Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics , 2016, Molecular Cancer Therapeutics.

[14]  B. Sullenger,et al.  From the RNA world to the clinic , 2016, Science.

[15]  Z. Ahmed,et al.  Long-term neuroprotection of retinal ganglion cells by inhibiting caspase-2 , 2016, Cell Death Discovery.

[16]  Jeremiah R. Brown,et al.  Hospital Mortality in the United States following Acute Kidney Injury , 2016, BioMed research international.

[17]  David C. Smith,et al.  A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC). , 2016 .

[18]  Y. Ramot,et al.  Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy , 2016, Toxicologic pathology.

[19]  R. Juliano,et al.  The delivery of therapeutic oligonucleotides , 2016, Nucleic acids research.

[20]  T. Conroy,et al.  Current standards and new innovative approaches for treatment of pancreatic cancer. , 2016, European journal of cancer.

[21]  V. Algalarrondo,et al.  TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies , 2016, Expert opinion on pharmacotherapy.

[22]  A. Scott,et al.  Antibody-mediated delivery of therapeutics for cancer therapy , 2016, Expert opinion on drug delivery.

[23]  Neal Rosen,et al.  Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism , 2016, Science.

[24]  W. Duan,et al.  Aptamers: A promising chemical antibody for cancer therapy , 2016, Oncotarget.

[25]  B. Hazenberg,et al.  First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy , 2016, Current opinion in neurology.

[26]  John J Rossi,et al.  RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise? , 2016, Annual review of pharmacology and toxicology.

[27]  Brian C. Stagg,et al.  Association of Anti-VEGF Injections with Progression of Geographic Atrophy , 2016, Ophthalmology and eye diseases.

[28]  N. Afshari,et al.  The impact of cataract surgery on cognitive function in an aging population , 2016, Current opinion in ophthalmology.

[29]  P. Cloetens,et al.  In vivo siRNA distribution and pharmacokinetics assessed by nuclear imaging are modulated according to radiolabelling site. , 2015, Nuclear medicine and biology.

[30]  P. Hawkins,et al.  Evolving landscape in the management of transthyretin amyloidosis , 2015, Annals of medicine.

[31]  Yechezkel Barenholz,et al.  Multistep, effective drug distribution within solid tumors , 2015, Oncotarget.

[32]  B. Bettencourt,et al.  Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study , 2015, Orphanet Journal of Rare Diseases.

[33]  J. Lieberman,et al.  Knocking down disease: a progress report on siRNA therapeutics , 2015, Nature Reviews Genetics.

[34]  S. Feng,et al.  Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents. , 2015, Nanomedicine.

[35]  Bulent Ozpolat,et al.  Preclinical and clinical development of siRNA-based therapeutics. , 2015, Advanced drug delivery reviews.

[36]  Xiaoqi Liu.  Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment , 2015, Translational oncology.

[37]  R. Eliakim,et al.  RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients , 2015, Oncotarget.

[38]  M. Dirin,et al.  Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[39]  R. Andersson,et al.  Update on the management of pancreatic cancer: surgery is not enough. , 2015, World journal of gastroenterology.

[40]  Mark A. Kay,et al.  Drugging RNAi , 2015, Science.

[41]  Malisa Sarntinoranont,et al.  Convection-enhanced delivery to the central nervous system. , 2015, Journal of neurosurgery.

[42]  S. Pfeffer,et al.  miR-122--a key factor and therapeutic target in liver disease. , 2015, Journal of hepatology.

[43]  Dan Peer,et al.  Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. , 2015, ACS nano.

[44]  Gurvinder Kaur,et al.  PLGA: a unique polymer for drug delivery. , 2015, Therapeutic delivery.

[45]  Anja van Brabant Smith,et al.  Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB–siRNA conjugates , 2014, Nucleic acids research.

[46]  D. Haussecker.  Current issues of RNAi therapeutics delivery and development. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[47]  Amy Chan,et al.  Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. , 2014, Journal of the American Chemical Society.

[48]  K. Giese,et al.  First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  L. van Doorn,et al.  In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor miR-122 , 2014, Antimicrobial Agents and Chemotherapy.

[50]  S. Zeuzem,et al.  Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. , 2014, Antiviral research.

[51]  R. Titze-de-Almeida,et al.  Interferon Gamma Potentiates the Injury Caused by MPP(+) on SH-SY5Y Cells, Which is Attenuated by the Nitric Oxide Synthases Inhibition , 2014, Neurochemical Research.

[52]  P. Svoboda.  Renaissance of mammalian endogenous RNAi , 2014, FEBS letters.

[53]  D. Kornbrust,et al.  Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. , 2014, Nucleic acid therapeutics.

[54]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[55]  S. Kauppinen,et al.  Development of microRNA therapeutics is coming of age , 2014, EMBO molecular medicine.

[56]  George A. Calin,et al.  RNAi Therapies: Drugging the Undruggable , 2014, Science Translational Medicine.

[57]  John C Hunter,et al.  In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C , 2014, Proceedings of the National Academy of Sciences.

[58]  Y. Sekijima.  Recent progress in the understanding and treatment of transthyretin amyloidosis , 2014, Journal of clinical pharmacy and therapeutics.

[59]  F. Medeiros,et al.  The pathophysiology and treatment of glaucoma: a review. , 2014, JAMA.

[60]  F. Muñoz,et al.  Phase 2 of bamosiran (SYL040012), a novel RNAi based compound for the treatment of increased intraocular pressure associated to glaucoma , 2014 .

[61]  C. Pañeda,et al.  SYL1001, a new treatment based on RNAi for the treatment of ocular pain. , 2014 .

[62]  T. R. Johnson,et al.  RTP801 gene expression is differentially upregulated in retinopathy and is silenced by PF-04523655, a 19-Mer siRNA directed against RTP801. , 2014, Investigative ophthalmology & visual science.

[63]  E. Gilboa,et al.  Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity. , 2014, The Journal of clinical investigation.

[64]  Y. Kopelman,et al.  Mutant KRAS is a druggable target for pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[65]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[66]  Daniel Anderson,et al.  Delivery materials for siRNA therapeutics. , 2013, Nature materials.

[67]  Joyce A. Wilson,et al.  Targeting miRNAs to treat Hepatitis C Virus infections and liver pathology: Inhibiting the virus and altering the host. , 2013, Pharmacological research.

[68]  B. Bettencourt,et al.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis. , 2013, The New England journal of medicine.

[69]  M. Borad,et al.  A phase I dose-escalation study of TKM-080301, a RNAi therapeutic directed against polo-like kinase 1 (PLK1), in patients with advanced solid tumors: Expansion cohort evaluation of biopsy samples for evidence of pharmacodynamic effects of PLK1 inhibition. , 2013 .

[70]  J. Doudna,et al.  Molecular mechanisms of RNA interference. , 2013, Annual review of biophysics.

[71]  S. Kauppinen,et al.  Treatment of HCV infection by targeting microRNA. , 2013, The New England journal of medicine.

[72]  M. Gilbert,et al.  Abstract LB-289: A phase I dose escalation study of TKM-080301, a RNAi therapeutic directed against PLK1, in patients with advanced solid tumors. , 2013 .

[73]  Z. Ahmed,et al.  University of Birmingham Pharmacological inhibition of caspase-2 protects axotomised retinal ganglion cells from apoptosis in adult rats , 2012 .

[74]  S. Kauppinen,et al.  Discovering the first microRNA-targeted drug , 2012, The Journal of cell biology.

[75]  R. Schachar,et al.  Evaluation of the siRNA PF-04523655 versus ranibizumab for the treatment of neovascular age-related macular degeneration (MONET Study). , 2012, Ophthalmology.

[76]  B. Molitoris,et al.  Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration. , 2012, Nucleic acid therapeutics.

[77]  C. Alabi,et al.  Attacking the genome: emerging siRNA nanocarriers from concept to clinic. , 2012, Current opinion in pharmacology.

[78]  Robert Persson,et al.  A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys. , 2012, Nucleic acid therapeutics.

[79]  A. Klippel,et al.  The interaction of PKN3 with RhoC promotes malignant growth , 2012, Molecular oncology.

[80]  R. Schachar,et al.  Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients , 2012, Eye.

[81]  J. Moreno-Montañés,et al.  SYL1001 for Treatment of Ocular Discomfort in Dry Eye: Safety and Tolerance (Phase I Study) , 2012 .

[82]  J. Burnett,et al.  RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.

[83]  G. Sobue,et al.  Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[84]  D. Brennan,et al.  Delayed Graft Function in the Kidney Transplant , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[85]  Yechezkel Barenholz,et al.  Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. , 2011, Advanced drug delivery reviews.

[86]  Won Jong Kim,et al.  Polymers in small-interfering RNA delivery. , 2011, Nucleic acid therapeutics.

[87]  A. Di Polo,et al.  Ocular neuroprotection by siRNA targeting caspase-2 , 2011, Cell Death and Disease.

[88]  A. Jiménez,et al.  SYL1001 Targeting TRPV1 Receptor for the Treatment of Ocular Pain associated to Dry Eye Syndrome , 2011 .

[89]  A. Judge,et al.  Abstract 2829: Preclinical characterization of TKM-080301, a lipid nanoparticle formulation of a small interfering RNA directed against polo-like kinase 1 , 2011 .

[90]  R. Ketting.  The many faces of RNAi. , 2011, Developmental cell.

[91]  B. Molitoris,et al.  Intravital Two-Photon Microscopy Assessment of Renal Protection Efficacy of siRNA for p53 in Experimental Rat Kidney Transplantation Models , 2010, Cell transplantation.

[92]  K. Giese,et al.  Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models , 2010, Clinical Cancer Research.

[93]  G. Shan.  RNA interference as a gene knockdown technique. , 2010, The international journal of biochemistry & cell biology.

[94]  T. R. Johnson,et al.  Dose-Related Gene Silencing of RTP801 With the siRNA PF04523655 in Long Evans Rat Models of STZ Induced Diabetes and Laser Induced CNV , 2010 .

[95]  S. Kauppinen,et al.  Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection , 2010, Science.

[96]  H. Soifer,et al.  Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents , 2009, Nucleic acids research.

[97]  L. Kisiswa,et al.  Retinal Ganglion Cell Death Postponed: Giving Apoptosis a Break? , 2009, Ophthalmic Research.

[98]  B. Molitoris,et al.  siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. , 2009, Journal of the American Society of Nephrology : JASN.

[99]  Peter H Lin,et al.  Current advances in research and clinical applications of PLGA-based nanotechnology , 2009, Expert review of molecular diagnostics.

[100]  J. Ambati,et al.  PF-04523655 (REDD14), an siRNA Compound Targeting RTP801, Penetrates Retinal Cells Producing Target Gene Knockdown and Avoiding TLR3 Activation , 2009 .

[101]  I. MacRae,et al.  The RNA-induced Silencing Complex: A Versatile Gene-silencing Machine* , 2009, The Journal of Biological Chemistry.

[102]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[103]  M. Manoharan,et al.  Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes. , 2009, Oligonucleotides.

[104]  E. Sontheimer,et al.  Origins and Mechanisms of miRNAs and siRNAs , 2009, Cell.

[105]  J. Doudna,et al.  A three-dimensional view of the molecular machinery of RNA interference , 2009, Nature.

[106]  B. Wiedenmann,et al.  Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. , 2008, Cancer research.

[107]  S. Miglior,et al.  Risk factors for glaucoma onset and progression. , 2008, Survey of ophthalmology.

[108]  G. Schenk,et al.  Drug targeting to the brain , 2008, Annual review of pharmacology and toxicology.

[109]  R. Boisgard,et al.  Molecular imaging study on in vivo distribution and pharmacokinetics of modified small interfering RNAs (siRNAs). , 2008, Oligonucleotides.

[110]  R. Funk,et al.  Neurodegenerative Diseases of the Retina and Potential for Protection and Recovery , 2008, Current neuropharmacology.

[111]  Ottrina S. Bond,et al.  Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes , 2008, Molecular vision.

[112]  S. Kauppinen,et al.  LNA-mediated microRNA silencing in non-human primates , 2008, Nature.

[113]  Justine R. Smith,et al.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3 , 2008, Nature.

[114]  E. Hoste,et al.  Epidemiology of acute kidney injury: How big is the problem? , 2008, Critical care medicine.

[115]  R. Boado.  Blood–brain Barrier Transport of Non-viral Gene and RNAi Therapeutics , 2007, Pharmaceutical Research.

[116]  W. Pardridge.  Drug Targeting to the Brain , 2007, Pharmaceutical Research.

[117]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[118]  L. Levin,et al.  Axonal loss and neuroprotection in optic neuropathies. , 2007, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

[119]  A. Szallasi,et al.  The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept , 2007, Nature Reviews Drug Discovery.

[120]  K. Eng,et al.  Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.

[121]  O. Boerman,et al.  INTRAVENOUSLY ADMINISTERED SHORT INTERFERING RNA ACCUMULATES IN THE KIDNEY AND SELECTIVELY SUPPRESSES GENE FUNCTION IN RENAL PROXIMAL TUBULES , 2006, Drug Metabolism and Disposition.

[122]  Yong Wang,et al.  Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras , 2006, Nature Biotechnology.

[123]  S. Kauppinen,et al.  LNA-modified oligonucleotides mediate specific inhibition of microRNA function. , 2006, Gene.

[124]  N. van der Velde,et al.  Syncope and falls due to timolol eye drops , 2006, BMJ : British Medical Journal.

[125]  A. Klippel,et al.  A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium , 2006, Gene Therapy.

[126]  J. Rossi.  RNAi therapeutics: SNALPing siRNAs in vivo , 2006, Gene Therapy.

[127]  P. Campochiaro.  Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders , 2006, Gene Therapy.

[128]  Keith Bowman,et al.  Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.

[129]  P. Whittaker,et al.  RNA interference: From gene silencing to gene-specific therapeutics , 2005, Pharmacology & Therapeutics.

[130]  Giuseppe Remuzzi,et al.  Delayed graft function in kidney transplantation , 2004, The Lancet.

[131]  P. Einat,et al.  Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. , 2004, Investigative ophthalmology & visual science.

[132]  T. Tuschl,et al.  Mechanisms of gene silencing by double-stranded RNA , 2004, Nature.

[133]  P. Khaw,et al.  Primary open-angle glaucoma , 2004, The Lancet.

[134]  Z. Paroo,et al.  Biodistribution of phosphodiester and phosphorothioate siRNA. , 2004, Bioorganic & medicinal chemistry letters.

[135]  Yang Shi,et al.  Small RNA: can RNA interference be exploited for therapy? , 2003, The Lancet.

[136]  W. Lieberthal,et al.  Role of apoptosis in the pathogenesis of acute renal failure , 2002, Current opinion in nephrology and hypertension.

[137]  R. Valuck,et al.  Systemic Adverse Effects of Ophthalmic β-Blockers , 2001 .

[138]  D. Rosenbaum,et al.  Cell‐specific caspase expression by different neuronal phenotypes in transient retinal ischemia , 2001, Journal of neurochemistry.

[139]  Amy A. Caudy,et al.  Post-transcriptional gene silencing by double-stranded RNA , 2001, Nature Reviews Genetics.

[140]  P. Sharp,et al.  RNAi Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals , 2000, Cell.

[141]  Y. Kurimoto,et al.  BDNF diminishes caspase-2 but not c-Jun immunoreactivity of neurons in retinal ganglion cell layer after transient ischemia. , 1999, Investigative ophthalmology & visual science.

[142]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[143]  G. Trainor,et al.  Biodistribution and metabolism of internally 3H-labeled oligonucleotides. I. Comparison of a phosphodiester and a phosphorothioate. , 1994, Molecular pharmacology.

[144]  J. Northrop,et al.  Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[145]  P. Lapalus,et al.  Autoradiographic localization of beta-adrenergic receptors in rabbit eye. , 1987, Investigative ophthalmology & visual science.

[146]  T. Friedmann,et al.  Gene Therapy for Human Genetic Disease? , 1972, Science.

[147]  A. Lotery,et al.  Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents , 2017, Eye.

[148]  S. Govoni,et al.  Targeting VEGF in eye neovascularization: What's new?: A comprehensive review on current therapies and oligonucleotide-based interventions under development. , 2016, Pharmacological research.

[149]  R. Titze-de-Almeida,et al.  The Presence of the Neuronal Nitric Oxide Synthase Isoform in the Intervertebral Disk , 2016, Neurotoxicity Research.

[150]  James O McNamara,et al.  Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells. , 2015, Methods in molecular biology.

[151]  M. V. González,et al.  In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[152]  J. Moreno-Montañés,et al.  Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[153]  H. Soifer,et al.  Silencing of gene expression by gymnotic delivery of antisense oligonucleotides. , 2012, Methods in molecular biology.

[154]  K. Giese,et al.  Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. , 2012, International journal of clinical pharmacology and therapeutics.

[155]  G. Hannon.  RNA interference : RNA , 2002 .

[156]  R. Valuck,et al.  Systemic adverse effects of ophthalmic beta-blockers. , 2001, The Annals of Pharmacotherapy.

[157]  S. Agrawal,et al.  Pharmacokinetics of Antisense Oligonucleotides , 1995, Clinical pharmacokinetics.